Wang S X
Changzheng Hospital, Second Military Medical College, Shanghai.
Zhonghua Zhong Liu Za Zhi. 1990 Jan;12(1):37-9.
This study was undertaken to evaluate the use of serum alpha 1-antitrypsin (alpha 1AT) in clinical diagnosis of primary hepatic carcinomas with monoclonal antibody-rate nephelometry. BALB/c mice were injected with human alpha 1AT. Spleen cells of the immunized mice and SP2/0 myeloma cells were hybridized in vitro. Monoclonal antibodies against alpha 1AT so obtained were used as detection agents in immuno-chemical monitor system (ICS). In 50 healthy individuals, serum alpha 1AT was 209 +/- 46.04 mg/dl. Serum alpha 1AT was determined in 49 patients with primary hepatic carcinoma, 26 with chronic active hepatitis and 26 with cirrhosis. Their positive rates were 43%, 3.8% and 0, respectively. Serum alpha 1AT level was significantly higher in primary hepatic carcinoma than in chronic active hepatitis and cirrhosis patients (P less than 0.001). No difference was found in alpha 1AT between patients with benign liver diseases and healthy adults (P greater than 0.05). The results indicate that alpha 1AT is useful in the diagnosis of primary hepatic carcinomas.
本研究旨在通过单克隆抗体速率散射比浊法评估血清α1-抗胰蛋白酶（α1AT）在原发性肝癌临床诊断中的应用。给BALB/c小鼠注射人α1AT。将免疫小鼠的脾细胞与SP2/0骨髓瘤细胞在体外进行杂交。如此获得的抗α1AT单克隆抗体用作免疫化学监测系统（ICS）中的检测试剂。50名健康个体的血清α1AT为209±46.04mg/dl。对49例原发性肝癌患者、26例慢性活动性肝炎患者和26例肝硬化患者测定了血清α1AT。它们的阳性率分别为43%、3.8%和0。原发性肝癌患者的血清α1AT水平显著高于慢性活动性肝炎和肝硬化患者（P<0.001）。良性肝病患者与健康成年人之间的α1AT无差异（P>0.05）。结果表明，α1AT对原发性肝癌的诊断有帮助。
